The FDA’s Oncologic Drugs Advisory Committee will meet on Tuesday, December 17, to review and discuss AstraZeneca’s (AZN +2%) marketing application for Lynparza (olaparib) for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic adenocarcinoma of the pancreas whose disease has not progressed on first-line platinum-based chemotherapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.